Table 3.

Incidence (%) of afatinib-associated major adverse events

Studya	Diarrhea		Skin rash		Stomatitis/mucositis
	All	≥ G3	All	≥ G3	All	≥ G3
Present study	68.9	3.4	44.8	0	68.9	3.4
LUX-Lung 36	95.2	14.4	89.1	16.2	72.1	8.7
LUX-Lung 3 – Japan26	100	22.2	100	20.4	90.7	7.4
LUX-Lung 67	88.3	5.4	80.8	14.6	51.9	5.4
LUX-Lung 79	91	13	88	9	64	4

Note:

^aAfatinib was the first-line treatment in the LUX-Lung studies.

Abbreviation: G3, grade 3.